Standardized peripheral blood mononuclear cell culture assay for zidovudine susceptibility testing of clinical human immunodeficiency virus type 1 isolates: effect of reducing the numbers of replicates and concentrations.
Zidovudine susceptibility was assessed for 525 clinical human immunodeficiency virus type 1 isolates, before and after reducing the number of replicates and zidovudine concentrations in the standardized consensus peripheral blood mononuclear cell culture assay. We conclude that omitting the 0.001 microM concentration and using duplicate rather than triplicate wells are valid and cost-effective modifications of this expensive assay.
Marschner
I C
IC
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts 02115, USA. marsch@sdac.harvard.edu
Mayers
D L
DL
Erice
A
A
Smeaton
L
L
Johnson
V A
VA
Richman
D D
DD
Reichelderfer
P
P
Japour
A J
AJ
D019380:Anti-HIV Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D003362:Cost-Benefit Analysis; D004352:Drug Resistance, Microbial; D005069:Evaluation Studies as Topic; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000187:drug effects* / Q000302:isolation & purification / Q000502:physiology; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000821:virology; D008826:Microbial Sensitivity Tests / Q000191:economics / Q000379:methods* / Q000592:standards*; D010641:Phenotype; D014779:Virus Replication / Q000187:drug effects; D015215:Zidovudine / Q000494:pharmacology*
D019380:Anti-HIV Agents; D015215:Zidovudine